10-Q: BioVie Q2 Loss Narrows, Advances Clinical Pipeline

BioVie Inc. reported a reduced net loss in its second fiscal quarter, driven by lower operating expenses, while advancing its Parkinson's and Long COVID clinical programs and preparing for a potential liver disease spin-off.

Summary

• Net loss for the three months ended December 31, 2025, decreased to $6.1 million from $7.1 million in the prior year period.
• Net loss for the six months ended December 31, 2025, was $11.2 million, comparable to $11.3 million in the prior year period.
• Cash and cash equivalents increased to $20.5 million as of December 31, 2025, from $17.5 million at June 30, 2025.
• Working capital stood at approximately $18.8 million as of December 31, 2025.
• The Phase 2b study of bezisterim for Parkinson's Disease completed enrollment of 60 patients in December 2025, with topline results expected in the first half of 2026.
• The Phase 2 ADDRESS-LC study for Long COVID, supported by a $13.1 million DOD grant, commenced in May 2025, with $6.4 million reimbursed as of January 20, 2026.
• The company is finalizing the protocol design for a Phase 3 study of BIV201 for liver cirrhosis and ascites.
• Option Therapeutics Inc. was established for a potential spin-off and IPO of the Liver Disease Program, with an S-1 registration statement filed on January 23, 2026.
• An underwritten public offering in August 2025 generated net proceeds of approximately $10.5 million.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a low score due to the explicit going concern warning, the severe setback in the Alzheimer's Phase 3 trial due to cGCP violations, and ongoing legal challenges, which overshadow the progress in other pipeline areas and the recent capital raise.

Positives

• Net loss decreased by $1.0 million for the three months ended December 31, 2025, compared to the same period in 2024, primarily due to lower operating expenses.
• Cash and cash equivalents increased to $20.5 million as of December 31, 2025, from $17.5 million at June 30, 2025, improving the company's liquidity position.
• Net cash used in operating activities significantly decreased to $7.5 million for the six months ended December 31, 2025, from $12.2 million in the prior year period.
• The Parkinson's Disease Phase 2b study successfully completed enrollment of 60 patients in December 2025, with topline results anticipated in the first half of 2026.
• The Long COVID program is advancing, with the Phase 2 ADDRESS-LC study commencing in May 2025 and significant grant reimbursements of $6.4 million received as of January 20, 2026, from the $13.1 million DOD grant.
• The potential spin-off and IPO of the Liver Disease Program through Option Therapeutics Inc. could unlock value and provide additional funding.
• A successful underwritten public offering in August 2025 raised approximately $10.5 million in net proceeds.

Negatives

• The company remains in a pre-revenue stage with no revenues expected in the foreseeable future.
• An accumulated deficit of approximately $363.3 million as of December 31, 2025, indicates significant historical losses.
• Management explicitly states that "These circumstances raise substantial doubt on the Company's ability to continue as a going concern."
• The Phase 3 Alzheimer's Disease trial was significantly compromised by "significant deviation from protocol and current good clinical practices (cGCPs) violations at 15 study sites," leading to patient exclusions and an underpowered trial.
• Ongoing legal proceedings, including a securities class action and three shareholder derivative lawsuits, allege material misrepresentations and breaches of fiduciary duties, incurring increased legal fees of approximately $546,000 for the six months ended December 31, 2025.
• R&D expenses increased by $511,000 for the six months ended December 31, 2025, primarily due to increased direct study costs for PD and Long COVID programs, despite a temporary curtailment of CMC expenses.

Risks

• Reliance on third parties (contract research organizations, clinical trial sites, manufacturers) to conduct clinical trials, with the risk that these parties may not successfully carry out contractual duties, meet deadlines, or comply with regulatory requirements, potentially delaying regulatory approval or commercialization.
• The company retains ultimate responsibility for ensuring studies comply with cGCPs, FDA IND requirements, and other regulations, and failures by third parties could necessitate additional clinical trials.
• Significant deviations from study protocol and cGCP violations at 15 sites in the Phase 3 Alzheimer's Disease trial raised questions about data validity and robustness, leading to an underpowered trial for primary endpoints.
• Future equity offerings or issuance of shares from options, warrants, or other arrangements could lead to significant dilution for existing stockholders.
• Warrants issued to Acuitas Group Holdings, LLC include price adjustment protection (down round features), which could further dilute existing stockholders if future capital raises occur at lower prices.
• The company is obligated to issue up to 180,000 shares of common stock upon achieving certain clinical, regulatory, and commercial milestones for its drug candidates, which would further dilute existing stockholders.
• The company's ability to continue as a going concern is uncertain, as it is pre-revenue and dependent on securing additional financing, which may not be available on acceptable terms or at all.
• The company is subject to ongoing legal proceedings, including a securities class action and shareholder derivative lawsuits, which could result in significant monetary damages, costs, and expenses, and divert management's attention.

Future Outlook

Topline results from the Parkinson's Disease Phase 2b study are expected in the first half of 2026. The company is considering employing an adaptive trial feature for the AD Phase 3 study or designing a new Phase 3 study leveraging recent scientific literature. The protocol design for the Phase 3 study of BIV201 for liver cirrhosis and ascites is being finalized. Option Therapeutics Inc. will commence operations upon the effective date of its potential IPO, which could lead to a spin-off of the Liver Disease Program. Future operations are dependent on the success of ongoing development and commercialization efforts and the ability to secure additional financing.

Management Comments

• "Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions."
• "Although management continues to pursue the Company's strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations."
• "The Company believes that the claims [in legal proceedings] are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome."

Industry Context

StockSavvy.ai notes that BioVie operates in highly competitive and capital-intensive therapeutic areas, including neurodegenerative diseases (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease. The company's strategy of developing novel small molecules and continuous infusion therapies positions it against established pharmaceutical players and numerous emerging biotechs. The potential spin-off of the Liver Disease Program into Option Therapeutics Inc. reflects a common industry trend to unlock value and attract specialized investment for distinct therapeutic pipelines, potentially allowing each program to pursue its own funding and strategic partnerships more effectively. The challenges faced in the AD Phase 3 trial highlight the inherent difficulties and high failure rates in neurodegenerative drug development, a common hurdle across the industry.

Comparison to Industry Standards

• The reported net loss of $11.2 million for the six months ended December 31, 2025, is typical for a clinical-stage biotechnology company with no revenue, as R&D expenses are substantial. For instance, similar-stage biotechs like ACADIA Pharmaceuticals (ACAD) or Anavex Life Sciences (AVXL) also report significant losses during their development phases, though their scale and pipeline maturity may differ.
• The cash position of $20.5 million and working capital of $18.8 million, while improved by a recent capital raise, are relatively modest for a company with multiple ongoing clinical trials (PD Phase 2b, Long COVID Phase 2, planned Liver Phase 3). This level of liquidity often necessitates frequent capital raises, a common characteristic for smaller biotechs, but also a source of dilution.
• The issues with the Alzheimer's Phase 3 trial, including cGCP violations and an underpowered study, are a significant setback. While clinical trial failures are common in the industry, such widespread protocol deviations are unusual and raise concerns about oversight, potentially impacting future regulatory interactions and investor confidence compared to peers who maintain stricter trial integrity.
• The $13.1 million DOD grant for the Long COVID program is a positive indicator of external validation and funding support, which is a competitive advantage for smaller biotechs seeking to de-risk their programs.

Corporate Governance

Legal Proceedings

• A securities class action complaint, Eric Olmstead v. BioVie Inc. et al., alleges material misrepresentations and/or omissions related to the NM101 Phase 3 AD study, covering the period from December 7, 2022, through November 28, 2023. The motion to dismiss was denied on March 27, 2025, and fact discovery is ongoing.
• Three shareholder derivative lawsuits (Andrew Hulm, William Settel, Cline Wilkerson) were consolidated, alleging breach of fiduciary duties, unjust enrichment, waste of corporate assets, gross mismanagement, and abuse of control. This action was stayed on January 27, 2026, pending resolution of a summary judgment motion in the Securities Class Action.

Related Party Transactions

• Acuitas Group Holdings, LLC, the company's largest stockholder and a former related party, holds warrants with down round features that resulted in deemed dividends due to subsequent capital raises. For example, the August 2025 capital raise reduced the exercise price from $13.70 to $2.50 per share, leading to a $43,544 deemed dividend for the three months ended September 30, 2025.

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity offerings, exercise of warrants (especially those with down round features), and issuance of shares for milestones. The going concern warning and legal proceedings pose substantial risks to investment value.
• Employees benefit from stock option grants as retention and incentive, but the company's going concern risk could impact job security and long-term compensation value.
• Future patients could potentially benefit from new therapies for Parkinson's, Long COVID, and liver disease if clinical trials are successful and regulatory approvals are obtained.
• Creditors face increased risk regarding the company's ability to meet its financial obligations in the long term without additional financing, as indicated by the going concern warning.
• Regulatory authorities (FDA, DOD) will continue scrutiny, especially following the cGCP violations in the AD trial. The DOD grant indicates a positive relationship for the Long COVID program.

Next Steps

• Topline results from the Parkinson's Disease Phase 2b trial are expected in the first half of 2026.
• The company is considering employing an adaptive trial feature or designing a new Phase 3 study for bezisterim in Alzheimer's Disease.
• Finalizing the protocol design for the Phase 3 study of BIV201 for liver cirrhosis and ascites.
• Option Therapeutics Inc. will commence operations upon the effective date of its potential IPO.
• The shares of common stock related to 803 vested RSUs will be issued and delivered by March 15, 2026.
• Fact discovery is ongoing in the Securities Class Action.
• The Consolidated Derivative Action is stayed pending resolution of a summary judgment motion in the Securities Class Action.
• Directors' stock options granted on January 5, 2026, will vest in installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026, or the 2026 annual shareholders' meeting.
• Employee stock options granted on January 5, 2026, will vest in equal installments on the first, second, and third Grant Date anniversary.
• RSUs awarded to a consultant on September 2, 2025, will vest in five equal installments at the Grant Date and over the next four calendar quarters beginning December 31, 2025.

Key Dates

Recommendation

The explicit "substantial doubt on the Company's ability to continue as a going concern" is a severe red flag for investors, indicating significant financial instability and a high risk of future capital raises that could lead to further dilution. The major setback in the Alzheimer's Phase 3 trial due to widespread cGCP violations raises serious questions about the company's operational integrity and ability to execute clinical programs effectively. Coupled with ongoing legal proceedings and a pre-revenue stage, the risks far outweigh the potential upside from pipeline progress, making the stock a strong sell for seasoned investors.

Keywords

Biotechnology, Clinical-stage, Neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disease, Long COVID, Liver disease, Ascites, Bezisterim (NE3107), BIV201, SEC filing, 10-Q, Clinical trials, Drug development, Biopharma, Going concern, Public offering, Warrants, Stock options, DOD grant, FDA approval, Corporate governance, Legal proceedings, Spin-off